Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amosartan dose-response in essential hypertension
NCT00942344Phase 2Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- May 2007
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Amosartan in essential hypertension (8 arms), sponsored by Hanmi Pharmaceutical. Primary endpoint: Seated Diastolic Blood Pressure at Week 8. Started May 2007; status: completed.
02
Drugs
Amosartan
03
Conditions
essential hypertension
Beyond the preview
Go deeper on NCT00942344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00942344.